延迟选择性淋巴结照射减少头颈癌放疗淋巴细胞损伤
在28例局部晚期头颈鳞癌患者中随机比较标准与延迟选择性淋巴结照射(ENI),延迟组先对大体肿瘤和受累淋巴结加量再行标准ENI。延迟ENI使初始PTV和全身剂量降低9.9倍和4.4倍,DNA损伤标志频率降低3-4倍,受损淋巴细胞约11%对约23%,并延缓淋巴细胞减少发生。
要点
- 延迟ENI降低初始PTV和全身剂量分别达9.9倍和4.4倍。
- 延迟ENI使DNA损伤标志频率降低3-4倍,受损淋巴细胞约11%对约23%。
- 延迟ENI保留第一周淋巴细胞计数并延缓淋巴细胞减少发生。
核心结论
- 延迟选择性淋巴结照射可能有助于在放疗期间保护循环免疫细胞,并为未来评估其增强放疗-免疫协同的前瞻性研究提供机制依据。
研究设计与样本
- 28例局部晚期头颈鳞癌患者被随机分配至标准或延迟ENI,其中辅助放疗13例、根治性放化疗15例。
- 延迟ENI采用先对大体肿瘤和受累淋巴结加量(辅助:2×2 Gy,n=6/15;根治:5×2 Gy,n=7/13)后再行标准ENI。
- 主要终点为淋巴细胞DNA损伤(γH2AX和53BP1焦点,n=25;双着丝粒染色体,n=9),次要终点包括白细胞转录组学(n=4)、淋巴细胞计数和淋巴细胞减少(n=28)。
主要发现
- 延迟ENI使初始计划靶体积和全身剂量分别降低9.9倍和4.4倍(均p<0.001)。
- 延迟ENI组DNA损伤标志频率降低3-4倍(p<0.001),受损淋巴细胞约11%对约23%(p<0.001)。
- 延迟ENI组第一治疗周基线淋巴细胞计数得以保持并延缓淋巴细胞减少发生,而标准ENI组淋巴细胞计数立即下降并出现淋巴细胞减少。
- 第一周淋巴细胞计数与计划靶体积、全身剂量和DNA损伤均呈负相关(均p<0.01)。
- 探索性转录组分析显示延迟ENI增强干扰素和代谢信号,而标准ENI优先激活炎症和损伤相关通路。
临床怎么用
- 在局部晚期头颈鳞癌放疗中,可考虑采用先对大体肿瘤和受累淋巴结加量、再行标准ENI的延迟策略以减少淋巴细胞损伤。
- 治疗第一周监测淋巴细胞计数可能有助于评估放疗诱导的淋巴细胞减少风险。
局限性
- 样本量较小(28例),转录组分析仅4例,属探索性研究。
- 部分终点仅在根治性放疗患者中评估,随访时间限于治疗期间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elective nodal irradiation (ENI) for locally advanced head-and-neck squamous cell carcinoma (LA-HNSCC) contributes to hematotoxicity and may impair radiotherapy-immunotherapy synergy. We investigated whether delayed ENI, using an upfront boost to gross disease and involved nodes followed by standard ENI, reduces radiation-induced lymphocyte DNA damage and lymphopenia (RIL) while modulating peripheral immune signaling compared with standard ENI. MATERIALS AND METHODS: Twenty-eight LA-HNSCC patients assigned for adjuvant (n = 13) or definitive (n = 15) (chemo)radiotherapy were randomized to standard or delayed ENI (upfront boost: adjuvant: 2 × 2 Gy, n = 6/15; definitive: 5 × 2 Gy, n = 7/13). Blood was collected pre-treatment, 15 min and 24 h after the first fraction, and (definitive only) before fraction six and at treatment end. Primary endpoints: DNA damage in lymphocytes via γH2AX and 53BP1 foci (n = 25, pre-therapy, post-first and pre-sixth fraction) and dicentric chromosomes (n = 9, pre-therapy and pre-sixth fraction). Secondary endpoints: exploratory leukocyte transcriptomics (n = 4; pre-therapy, pre-sixth fraction and end of therapy), lymphocyte counts, and RIL (n = 28; pre-therapy and weekly during therapy). RESULTS: Delayed ENI reduced initial planning target volume and whole-body dose by 9.9- and 4.4-fold (both p < 0.001), resulting in 3-4-fold lower DNA damage marker frequencies (p < 0.001) and fewer radiation-damaged lymphocytes (~11% vs. ~23%, p < 0.001). Baseline lymphocyte counts were preserved during the first treatment week, delaying RIL onset, whereas standard ENI induced an immediate decline in lymphocyte counts and RIL. Week 1 lymphocyte counts inversely correlated with planning target volume, whole-body dose, and DNA damage (all p < 0.01). Exploratory transcriptomic profiling revealed enhanced interferon and metabolic signaling with delayed ENI, whereas standard ENI preferentially activated inflammatory and damage-associated pathways. CONCLUSION: These findings suggest that delaying elective nodal irradiation may help preserve circulating immune cells during radiotherapy and provide a mechanistic rationale for future prospective studies evaluating whether this strategy can enhance radiotherapy-immunotherapy synergy in LA-HNSCC.
引用
- Kaufmann J, Salah A, Marini F, et al. Delayed elective nodal irradiation in head-and-neck cancer radiotherapy reduces acute lymphocyte damage, lymphopenia, and modulates immune signatures. Clin Transl Radiat Oncol. 2026. PMID: 42893008. doi:10.1016/j.ctro.2026.101315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。